<DOC>
	<DOCNO>NCT01486004</DOCNO>
	<brief_summary>The purpose study investigate effect steady-state concentration TMC435 ( administer day ) steady-state pharmacokinetics ethinylestradiol norethindrone ( administer day ) level progesterone , luteinizing hormone follicle-stimulating hormone , healthy female participant . Ethinlyestradiol norethindrone synthetic hormone , constitute oral contraceptive Ovysmen . Also short-term safety tolerability co-administration TMC435 Ovysmen study . Steady-state term mean drug give long enough plasma concentration remain subsequent dose . TMC435 investigate treatment chronic hepatitis C virus ( HCV ) infection . Pharmacokinetics ( PK ) mean drug absorb bloodstream , distribute body eliminate body . A contraceptive method prevents pregnancy .</brief_summary>
	<brief_title>A Study Healthy Female Participants Investigating Effect TMC435 Pharmacokinetics Synthetic Hormones Oral Contraceptive Ovysmen</brief_title>
	<detailed_description>This Phase I , open-label ( participant investigator know name medication give certain moment ) trial 18 healthy female participant investigate effect TMC435 steady-state steady-state pharmacokinetics ethinlyestradiol norethindrone . Ethinylestradiol ( 35 Âµg ) norethindrone ( 1.0 mg ) component Ovysmen , widely use oral contraceptive ( OC ) . All subject receive OC therapy 2 complete OC cycle . During first cycle , participant receive Ovysmen alone , daily , first 21 day . An OC- free period respect Day22 till include Day28 . During second OC cycle , participant receive Ovysmen daily first 21 day plus TMC435 150 mg daily Day12 till include Day21 . Next , OC-free period Day22 till include Day28 establish . Full 24-hour PK profile ethinylestradiol norethindrone determine last day OC treatment first OC cycle ( i.e . Day21 ) last day OC treatment second OC cycle ( i.e . Day21 ) . Full 24-hour PK profile TMC435 determine Day21 second OC cycle . Pharmacodynamic ( body react drug ) assessments serum level progesterone , luteinizing hormone follicle-stimulating hormone ( hormone involve ovulation preparation womb pregnancy ) do Day1 , 19 , 20 21 OC cycle . Safety tolerability assess study period follow . Blood urine safety sample , electrocardiogram ( ECG ) vital sign ( blood pressure heart rate ) take screening , Day1 , Day21 Day22 OC cycle , follow-up visit 5 7 day last TMC435 intake . A physical examination perform screening , Day1 Day20 OC cycle , follow-up visit 5 7 day last TMC435 intake . Participants admit unit Day20 morning discharge Day22 , OC cycle .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<criteria>Participants must practice highly effective method birth control entry agree continue use method throughout study least 30 day last administration study drug nonsmoker least 3 month prior screen Women pregnant , breastfeeding , premenopausal postmenopausal A positive Human Immunodeficiency Virus ( HIV ) 1 HIV2 test screen A positive Hepatitis A , B C test screen A clinical significant abnormal find gynaecological examination</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>TMC435</keyword>
	<keyword>TMC435-TiDP16-C124</keyword>
	<keyword>TMC435-C124</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hep C</keyword>
	<keyword>Healthy participant</keyword>
</DOC>